Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Assets (2016 - 2026)

Bio-Techne has reported Assets over the past 17 years, most recently at $2.5 billion for Q4 2025.

  • For Q4 2025, Assets fell 5.53% year-over-year to $2.5 billion; the TTM value through Dec 2025 reached $2.5 billion, down 5.53%, while the annual FY2025 figure was $2.6 billion, 5.4% down from the prior year.
  • Assets for Q4 2025 was $2.5 billion at Bio-Techne, roughly flat from $2.5 billion in the prior quarter.
  • Over five years, Assets peaked at $2.8 billion in Q3 2023 and troughed at $2.1 billion in Q1 2021.
  • A 5-year average of $2.5 billion and a median of $2.5 billion in 2025 define the central range for Assets.
  • Biggest five-year swings in Assets: rose 17.21% in 2023 and later fell 7.67% in 2025.
  • Year by year, Assets stood at $2.3 billion in 2021, then increased by 2.54% to $2.4 billion in 2022, then increased by 15.54% to $2.7 billion in 2023, then decreased by 2.21% to $2.7 billion in 2024, then fell by 5.53% to $2.5 billion in 2025.
  • Business Quant data shows Assets for TECH at $2.5 billion in Q4 2025, $2.5 billion in Q3 2025, and $2.6 billion in Q2 2025.